Serán BioScience, a contract development and manufacturing organization (CDMO), has announced a strategic growth transaction of more than $200 million.
- Serán partnered with Bain Capital in a strategic growth transaction to build a new commercial facility in Bend, Oregon.
- The $200 million growth transaction will enable building of a commercial drug product facility to be completed in 2026
The investment, led by Bain Capital Life Sciences, aims to support the company’s continued expansion, with existing investor Vivo Capital remaining a key shareholder. The partnership will support the development of a cutting-edge, commercial-scale facility in Bend, Oregon, focused on spray drying, particle engineering, and finished dose manufacturing.
“This transaction is a significant milestone in Serán’s evolution. It will enable us to rapidly scale our clinical manufacturing capability and support the launch of new medicines.”
Dan Smithey, Co-Founder and CEO of Serán
The 200,000 sq.ft. campus will enhance Serán’s ability to provide integrated solutions for drug delivery across various modalities, including oral, pulmonary, and nasal routes. The plant will feature advanced particle engineering technologies such as spray drying, hot melt extrusion, nano-milling, and fluid-bed manufacturing, alongside finished dose capabilities like tableting, encapsulation, and powder filling for modified release products.
An adjacent site, already under construction, will further expand the company’s packaging, labelling, serialization, and distribution offerings.
Bain Capital’s Managing Director, Will Cozean, expressed confidence in Serán’s ability to grow, noting, “We believe the company is well-positioned to address the challenges facing next-generation oral drugs.”
Find out more at SeranBio.com, There’s a Science to Success™
Overview of outsourcing trends 
